Phase II Study of Calcitonin for Tumoral Calcinosis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of
calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact
parathyroid hormone levels in patients with tumoral calcinosis.
II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine whether
hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus.
IV. Determine how repetitive calcitonin administration alters the biochemical markers of bone
metabolism in osteopenic patients with tumoral calcinosis.
Phase:
Phase 2
Details
Lead Sponsor:
National Center for Research Resources (NCRR)
Collaborator:
Ann & Robert H Lurie Children's Hospital of Chicago